EP Patent

EP3517536A1 — Aminotriazine derivatives useful as tank-binding kinase inhibitor compounds

Assigned to Gilead Sciences Inc · Expires 2019-07-31 · 7y expired

What this patent protects

Compounds having the following formula (I) and methods of their use and preparation are disclosed:(I).

USPTO Abstract

Compounds having the following formula (I) and methods of their use and preparation are disclosed:(I).

Drugs covered by this patent

momelotinib-dihydrochloride (MOMELOTINIB DIHYDROCHLORIDE)

Patent Metadata

Patent number: EP3517536A1
Jurisdiction: EP
Classification: —
Expires: 2019-07-31
Drug substance claim: No
Drug product claim: No
Assignee: Gilead Sciences Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.